AU2021279280A1 - Azelastine as antiviral treatment - Google Patents
Azelastine as antiviral treatment Download PDFInfo
- Publication number
- AU2021279280A1 AU2021279280A1 AU2021279280A AU2021279280A AU2021279280A1 AU 2021279280 A1 AU2021279280 A1 AU 2021279280A1 AU 2021279280 A AU2021279280 A AU 2021279280A AU 2021279280 A AU2021279280 A AU 2021279280A AU 2021279280 A1 AU2021279280 A1 AU 2021279280A1
- Authority
- AU
- Australia
- Prior art keywords
- azelastine
- virus
- cov
- sars
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20177451 | 2020-05-29 | ||
| EP20177451.0 | 2020-05-29 | ||
| EP20184767.0 | 2020-07-08 | ||
| EP20184767.0A EP3936132A1 (en) | 2020-07-08 | 2020-07-08 | Azelastine as antiviral treatment |
| EP20195740 | 2020-09-11 | ||
| EP20195740.4 | 2020-09-11 | ||
| EP21171333 | 2021-04-29 | ||
| EP21171333.4 | 2021-04-29 | ||
| PCT/EP2021/064338 WO2021239943A1 (en) | 2020-05-29 | 2021-05-28 | Azelastine as antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021279280A1 true AU2021279280A1 (en) | 2023-01-05 |
Family
ID=76059910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021279280A Pending AU2021279280A1 (en) | 2020-05-29 | 2021-05-28 | Azelastine as antiviral treatment |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20230201216A1 (https=) |
| EP (2) | EP3934653B1 (https=) |
| JP (1) | JP2023529025A (https=) |
| KR (1) | KR20230021009A (https=) |
| CN (1) | CN116406273A (https=) |
| AU (1) | AU2021279280A1 (https=) |
| BR (1) | BR112022023897A2 (https=) |
| CA (1) | CA3184167A1 (https=) |
| DK (1) | DK3934653T3 (https=) |
| ES (1) | ES2937145T3 (https=) |
| FI (1) | FI3934653T3 (https=) |
| HU (1) | HUE060929T2 (https=) |
| IL (1) | IL298543A (https=) |
| JO (1) | JOP20220319B1 (https=) |
| LT (1) | LT3934653T (https=) |
| MX (1) | MX2022015074A (https=) |
| PL (1) | PL3934653T3 (https=) |
| RS (1) | RS63940B1 (https=) |
| SI (1) | SI3934653T1 (https=) |
| SM (1) | SMT202300036T1 (https=) |
| WO (1) | WO2021239943A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11806359B2 (en) | 2020-03-31 | 2023-11-07 | Phoenix Biotechnology, Inc. | Method and compositions for treating Coronavirus infection |
| ES2937145T3 (es) * | 2020-05-29 | 2023-03-24 | CEBINA GmbH | Azelastina como tratamiento antiviral |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3877904D1 (de) * | 1987-11-13 | 1993-03-11 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
| DE3836579A1 (de) * | 1987-11-13 | 1989-05-24 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| US8758816B2 (en) * | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| JP2008285474A (ja) | 2007-04-17 | 2008-11-27 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤を含有する医薬組成物 |
| US8642069B2 (en) * | 2008-08-27 | 2014-02-04 | Alexander D. Goldin | Composition and method for treating colds |
| WO2021207213A2 (en) * | 2020-04-07 | 2021-10-14 | University Of Florida Research Foundation, Incorporated | Methods to prevent sars-cov-2 infection and treat covid-19 |
| US20230142221A1 (en) * | 2020-04-10 | 2023-05-11 | Kamal Khan Mubarak | Compositions and methods for modulating ace2 receptor |
| CN113521289A (zh) * | 2020-04-16 | 2021-10-22 | 中国科学院上海药物研究所 | 15种药物有效成分在抗病毒感染中的应用 |
| ES2937145T3 (es) * | 2020-05-29 | 2023-03-24 | CEBINA GmbH | Azelastina como tratamiento antiviral |
-
2021
- 2021-05-28 ES ES21727186T patent/ES2937145T3/es active Active
- 2021-05-28 CA CA3184167A patent/CA3184167A1/en active Pending
- 2021-05-28 WO PCT/EP2021/064338 patent/WO2021239943A1/en not_active Ceased
- 2021-05-28 HU HUE21727186A patent/HUE060929T2/hu unknown
- 2021-05-28 US US17/928,422 patent/US20230201216A1/en active Pending
- 2021-05-28 AU AU2021279280A patent/AU2021279280A1/en active Pending
- 2021-05-28 PL PL21727186.5T patent/PL3934653T3/pl unknown
- 2021-05-28 KR KR1020227045014A patent/KR20230021009A/ko active Pending
- 2021-05-28 JP JP2023516644A patent/JP2023529025A/ja active Pending
- 2021-05-28 LT LTEPPCT/EP2021/064338T patent/LT3934653T/lt unknown
- 2021-05-28 SI SI202130029T patent/SI3934653T1/sl unknown
- 2021-05-28 DK DK21727186.5T patent/DK3934653T3/da active
- 2021-05-28 FI FIEP21727186.5T patent/FI3934653T3/fi active
- 2021-05-28 IL IL298543A patent/IL298543A/en unknown
- 2021-05-28 MX MX2022015074A patent/MX2022015074A/es unknown
- 2021-05-28 CN CN202180059038.4A patent/CN116406273A/zh active Pending
- 2021-05-28 US US17/333,857 patent/US11273163B2/en active Active
- 2021-05-28 EP EP21727186.5A patent/EP3934653B1/en active Active
- 2021-05-28 RS RS20230083A patent/RS63940B1/sr unknown
- 2021-05-28 SM SM20230036T patent/SMT202300036T1/it unknown
- 2021-05-28 EP EP22206040.2A patent/EP4190333A1/en active Pending
- 2021-05-28 BR BR112022023897A patent/BR112022023897A2/pt unknown
- 2021-12-27 US US17/562,973 patent/US11433080B2/en active Active
-
2022
- 2022-11-21 JO JOJO/P/2022/0319A patent/JOP20220319B1/ar active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3934653A1 (en) | 2022-01-12 |
| SMT202300036T1 (it) | 2023-03-17 |
| MX2022015074A (es) | 2023-02-16 |
| PL3934653T3 (pl) | 2023-03-13 |
| US11273163B2 (en) | 2022-03-15 |
| EP4190333A1 (en) | 2023-06-07 |
| RS63940B1 (sr) | 2023-02-28 |
| HUE060929T2 (hu) | 2023-04-28 |
| EP3934653B1 (en) | 2022-11-09 |
| FI3934653T3 (fi) | 2023-03-01 |
| IL298543A (en) | 2023-01-01 |
| BR112022023897A2 (pt) | 2023-04-04 |
| KR20230021009A (ko) | 2023-02-13 |
| ES2937145T3 (es) | 2023-03-24 |
| WO2021239943A1 (en) | 2021-12-02 |
| SI3934653T1 (sl) | 2023-04-28 |
| CN116406273A (zh) | 2023-07-07 |
| CA3184167A1 (en) | 2021-12-02 |
| JOP20220319B1 (ar) | 2024-12-22 |
| JP2023529025A (ja) | 2023-07-06 |
| US11433080B2 (en) | 2022-09-06 |
| US20230201216A1 (en) | 2023-06-29 |
| US20210369730A1 (en) | 2021-12-02 |
| LT3934653T (lt) | 2023-02-27 |
| DK3934653T3 (da) | 2023-02-13 |
| US20220143040A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7019727B2 (ja) | インフルエンザの治療方法 | |
| JP6567781B2 (ja) | ウイルス感染症の治療用チアゾリド化合物 | |
| US11433080B2 (en) | Antiviral treatment | |
| WO2020241759A1 (ja) | インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤 | |
| CN112912074A (zh) | Egcg-棕榈酸酯组合物及其使用方法 | |
| US20230225988A1 (en) | Antiviral use of calixarenes | |
| WO2014146218A1 (zh) | 马替麦考酚酯或其盐类用于制备抗流感病毒之药物的用途 | |
| RU2842052C1 (ru) | Азеластин в качестве противовирусного лечения | |
| TWI594755B (zh) | 投予依立托倫或其醫藥上可接受的鹽以治療正黏液病毒感染 | |
| EP3936132A1 (en) | Azelastine as antiviral treatment | |
| HK40087524A (zh) | 氮卓斯汀用作抗病毒治疗 | |
| CN115916189A (zh) | 治疗严重急性呼吸综合征的方法 | |
| CN105920004B (zh) | 1，2，4-三取代哌嗪化合物在制备抗流感病毒药物中的用途 | |
| WO2020216349A1 (zh) | 一种肠道病毒抑制剂 | |
| CN117838698A (zh) | 奥拉替尼在制备治疗流感病毒感染的药物中的应用 | |
| EA048350B1 (ru) | Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви | |
| HK40090314A (zh) | 治疗严重急性呼吸综合征的方法 | |
| HK40017310B (en) | Methods of treating influenza | |
| HK40017310A (en) | Methods of treating influenza |